MARIE PAUL GATSIMBANYI: Open Payments
NPI 1598514986 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$514 in 21 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $223 · 2025 $514
Food & beverage: $514
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $224 |
| Lilly USA, LLC | 5 | $78 |
| Novo Nordisk Inc | 2 | $53 |
| SANOFI-AVENTIS U.S. LLC | 1 | $51 |
| Amgen Inc. | 1 | $47 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $29 |
| Janssen Pharmaceuticals, Inc | 1 | $18 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $15 |
Products named: FARXIGA, TZIELD, MOUNJARO, REPATHA, BREZTRI, Wegovy, Kerendia, JARDIANCE.
Industry payments across AZ — which companies pay providers there.
